{
    "clinical_study": {
        "@rank": "124478", 
        "acronym": "CONSTELLATION", 
        "arm_group": {
            "arm_group_label": "Main group", 
            "arm_group_type": "Experimental", 
            "description": "All patients enrolled in the study (155 patients) will start in this main group. They will receive 6 ranibizumab injections (one per month from baseline to month 5, 0.5 mg of ranibizumab per injection). After this intensive follow up phase, injection will be done every 3 months until month 24. If a patient does not meet the criteria to stay in the main group, he/she will be directed to the rescue group, where monitoring and treatment is recommended to be performed according to the SmPC of Lucentis\u00ae (ranibizumab) (PRN with monthly follow up)"
        }, 
        "brief_summary": {
            "textblock": "To evaluate a new treatment regimen with a spaced out follow-up after an initial intensive\n      treatment phase in patients with reduced visual acuity due to diabetic macular edema (DME)."
        }, 
        "brief_title": "Efficacy and Safety of Lucentis\u00ae Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Macular Edema", 
            "Macular Degeneration", 
            "Diabetes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Degeneration", 
                "Macular Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type I or type II diabetes with HbA1c\u226410%\n\n          -  Visual impairment due to a diabetic macular edema\n\n          -  Stable antidiabetic treatment (since more than 3 months) or hygiene-dietary\n\n        Exclusion Criteria:\n\n          -  Inflammation or infection in one eye\n\n          -  Women of childbearing potential without an efficient contraception, pregnant or\n             breastfeeding\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "155", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02032173", 
            "org_study_id": "CRFB002DFR11"
        }, 
        "intervention": {
            "arm_group_label": "Main group", 
            "description": "Patient will start in the main group with 6 monthly ranimizumab IVTs until month 5. Additional mandatory IVTs will be done at months 8 and 11. At months 14, 17, 20 and 23, IVTs will be done if BCVA loss is comprised between 9 and 5 letters (included). If patient did not loose more than 4 letters, no injection has to be performed at the visit. Criteria to stay in the main group are : 1\u00b0) at Month 3, 4 letters (included) improvement compared to baseline (Day 0) OR an improvement in CSF \u2265 0.1 log OCT compared to baseline (Day 0); 2\u00b0) at Month 6, a stable VA is obtained based on the months 4, 5 and 6 BCVA score; 3\u00b0) at Months 8, 11, 14, 17, 20 and 23, no BCVA decrease by more than 10 letters (excluded) compared with the highest BCVA score since the beginning of the study.", 
            "intervention_name": "Main group", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ranibizumab", 
            "Diabetic Macular Edema"
        ], 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Le Kremlin Bicetre Cedex", 
                    "country": "France", 
                    "zip": "94275"
                }, 
                "name": "Novartis Investigative Site"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "A 24 Month Open-label, Multicenter, Phase IIIb Study of the Efficacy and Safety of Lucentis\u00ae (Ranibizumab 0,5mg) in Diabetic Patients With Visual Impairment Due to Macular Edema Evaluating a Spaced Out Follow-up After Intensive Loading Phase", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Best-Corrected Visual Acuity (BCVA) is measured using an Early Treatment of Diabetic Retinopathy Study scale (ETDRS scale) at 4m. The BCVA score at 6 and 24 months visits will be used. The rate of patients with a stable BCVA (BCVA score at 6 months minus BCVA score at 24 months \u22644 letters) will be calculated as well as its confidence interval at 95%", 
            "measure": "Rate of patients with a stable BCVA at 24 months compared with BCVA at 6 months", 
            "safety_issue": "No", 
            "time_frame": "6 months and 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02032173"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "BCVA is measured using an ETDRS scale at 4m. The BCVA score at 11 and 24 months visits will be used. The rate of patients with a stable BCVA (BCVA score at 11 months minus BCVA score at 24 months \u22644 letters) will be calculated.", 
                "measure": "Rate of patients will a stable BCVA at 24 months compared with BCVA at 11 months", 
                "safety_issue": "No", 
                "time_frame": "month 11 and month 24"
            }, 
            {
                "description": "The rates of patients with a BCVA score \u226510 letters for each of the following visits (months 3, 6, 8, 11, 14, 17, 20, 23 and 24) compared with baseline (day 0) will be calculated.", 
                "measure": "Rate of patients keeping a BCVA score gain \u226510 letters", 
                "safety_issue": "No", 
                "time_frame": "baseline, months 3, 6, 8, 11, 14, 17, 20, 23 and 24"
            }, 
            {
                "description": "The rates of patients with a BCVA score \u226515 letters for each of the following visits (months 3, 6, 8, 11, 14, 17, 20, 23 and 24) compared with baseline (day 0) will be calculated.", 
                "measure": "Rate of patients keeping a BCVA score gain \u226515 letters", 
                "safety_issue": "No", 
                "time_frame": "baseline, months 3, 6, 8, 11, 14, 17, 20, 23 and 24"
            }, 
            {
                "description": "BCVA scores for all visits between baseline and month 24 from both main and rescue groups are recorded. The mean absolute variations are calculated from baseline score.", 
                "measure": "BCVA mean absolute variation from baseline to 24 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline, months 1, 2, 3, 4, 5, 6, 8, 11, 14, 17, 20, 23 and 24"
            }, 
            {
                "description": "The absolute variations of the Central Subfield Thickness (CST) measured using a Spectral Domain-Optical Coherence Tomography (SD-OCT) at each visit is calculated from baseline score and for both main and rescue groups. Values can also be calculated as a log OCT (=log[CST/200]).", 
                "measure": "CST evaluation", 
                "safety_issue": "No", 
                "time_frame": "baseline, months 1, 2, 3, 4, 5, 6, 8, 11, 14, 17, 20, 23 and 24"
            }, 
            {
                "description": "Change of CST and BCVA score of patients from the rescue group.", 
                "measure": "Effect of follow-up change on CST and BCVA in rescue group", 
                "safety_issue": "No", 
                "time_frame": "months 6, 12, 18 and 24"
            }, 
            {
                "description": "The rate of patients with a BCVA loss \u226515 letters compared with month 6 BCVA score leading to a change of group (Rescue group) evaluated from each visit onwards stating at month 6.", 
                "measure": "Rate of patients with a BCVA loss \u226515 letters compared with month 6", 
                "safety_issue": "No", 
                "time_frame": "Months 6, 8, 11, 14, 17, 20, 23 and 24"
            }, 
            {
                "description": "Frequency of  Adverse Events (AEs) and Serious Adverse Events (SAEs) directly reported by patients or by the physician during a study visit as well as systolic and diastolic blood pressure (absolute values and variation from baseline) will be reported.", 
                "measure": "Number of participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "up month 24"
            }, 
            {
                "description": "The global score obtained on the Visual Function Questionnaire 25 (VFQ 25) will be compared from baseline to months 11 and 24 for the Main group and from baseline to months 12 and 24 for the Rescue group.", 
                "measure": "Evaluation of the spaced out follow-up on visual functions and quality of life", 
                "safety_issue": "No", 
                "time_frame": "baseline, months 11, 12 and 24"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}